You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CISPLATIN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for cisplatin and what is the scope of freedom to operate?

Cisplatin is the generic ingredient in three branded drugs marketed by Accord Hlthcare, Bedford, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hq Spclt Pharma, Norvium Bioscience, Pharmachemie Bv, Qilu, and Teva Pharms Usa, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for cisplatin. Ten suppliers are listed for this compound.

Summary for CISPLATIN
US Patents:0
Tradenames:3
Applicants:10
NDAs:10
Drug Master File Entries: 14
Finished Product Suppliers / Packagers: 10
Clinical Trials: 3,887
Drug Prices: Drug price trends for CISPLATIN
What excipients (inactive ingredients) are in CISPLATIN?CISPLATIN excipients list
DailyMed Link:CISPLATIN at DailyMed
Drug Prices for CISPLATIN

See drug prices for CISPLATIN

Recent Clinical Trials for CISPLATIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
EMD SeronoPhase 1
Fundación para el Progreso de la Oncología en CantabriaPhase 2
Regeneron PharmaceuticalsPhase 2

See all CISPLATIN clinical trials

Pharmacology for CISPLATIN
Medical Subject Heading (MeSH) Categories for CISPLATIN

US Patents and Regulatory Information for CISPLATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Qilu CISPLATIN cisplatin INJECTABLE;INJECTION 218868-001 May 10, 2024 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa CISPLATIN cisplatin INJECTABLE;INJECTION 074735-001 Jul 16, 1999 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hq Spclt Pharma PLATINOL cisplatin INJECTABLE;INJECTION 018057-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience CISPLATIN cisplatin INJECTABLE;INJECTION 091062-001 Apr 18, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CISPLATIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hq Spclt Pharma CISPLATIN cisplatin INJECTABLE;INJECTION 018057-004 Nov 8, 1988 ⤷  Sign Up ⤷  Sign Up
Hq Spclt Pharma CISPLATIN cisplatin INJECTABLE;INJECTION 018057-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Hq Spclt Pharma CISPLATIN cisplatin INJECTABLE;INJECTION 018057-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Hq Spclt Pharma PLATINOL-AQ cisplatin INJECTABLE;INJECTION 018057-003 Jul 18, 1984 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.